性能参数 |
|||
产品名称 |
COTI-2 |
||
规格 |
5mg 10mg 25mg |
||
货号 |
GOY-Y2202 |
||
含量 |
>98.00% |
||
CAS |
1039455-84-9 |
||
别名 |
|
|
|
化学名 |
4-(2-pyridinyl)-2-(6,7-dihydro-8(5H)-quinolinylidene)hydrazide-1-piperazinecarbothioic acid |
分子式 |
C19H22N6S |
分子量 |
分子 366.5 |
溶解度 |
≤1mg/ml in DMSO;2.5mg/ml in dimethyl formamide |
储存条件 |
Store at -20°C |
General tips |
|
用途 |
仅供科研 |
价格 |
电询 |
|
|||
详细内容 |
p53 has varoius mechanisms of anticancer function and plays a critical role in genomic stability, apoptosis and inhibition of angiogenesis. In vitro: Previous study tested the efficacy of COTI-2 against a diverse group of human cancer cell lines with different genetic mutation backgrounds. Results showed that COTI-2 efficiently inhibited the proliferation rate of all the tested cell lines following 72 h of treatment. Most cell lines showed nanomolar sensitivity to COTI-2 treatment. In addition, COTI-2 was significantly more effective at inhibiting tumor cell proliferation than either cetuximab or erlotinib in COLO-205, HCT-15, and SW620 cell lines. Notably, all three lines were insensitive to growth inhibition to any degree in response to low concentrations of cetuximab and erlotinib, but highly sensitive to even low doses of COTI-2 [1]. In vivo: The effects of COTI-2 on inhibiting the growth of HT-29 and SHP-77 xenografts in immunocompromised mice was assessed when intraperitoneally administered. It was found that COTI-2 at 10 mg/kg could significantly inhibit tumor growth in the HT-29 human colorectal tumor xenografts. In addition to reducing tumor volumes at specific times post-treatment, COTI-2 could also delay the time required for tumors to reach specified volumes [1]. Clinical trial: A study of COTI-2 for the treatment of advanced or recurrent gynecologic malignancies is currently recruiting patients [2]. References: [1] Salim, K. Y.,Vareki, S.M.,Danter, W.R., et al. COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo. Oncotarget 7(27), (2016). [2] https://clinicaltrials. gov/ct2/show/NCT02433626term=COTI-2&rank=1 |
公司正在销售的产品:
(+/-)-儿茶精 96% L-焦谷氨酸叔丁酯 98% 表儿茶素没食子酸酯 分析标准品,≥98% (R)-(+)-N-苄基-1-苯乙胺 98% 表儿茶素没食子酸酯 98% (-)-10-樟脑磺酰氯 97% 表儿茶素 分析标准品,≥98% (1S)-(+)-樟脑-10-磺酰氯 97% (-)-表没食子儿茶素没食子酸酯 分析标准品,≥98% (1R,2S)-(+)-2,10-樟脑内磺酰胺 97% D-半乳糖 98% (-)-10,2-樟脑磺内酰胺 99% |
CEP-3249610mM (in 1mL DMSO) 5mg 25mg 100mg>98.00%Cas No. 1188910-76-0C24H22F3N5O5 Cobimetinib (racemate)5mg 10mg 25mg 50mg>98.00%Cas No. 934662-91-6C21H21F3IN3O2 Cobimetinib (R-enantiomer)5mg 10mg 25mg 50mg>98.00%Cas No. 934660-94-3C21H21F3IN3O2 CHPG5mg 10mg 25mg 50mg>98.00%Cas No. 170846-74-9C8H8NO3Cl Dabrafenib Mesylate (GSK-2118436)10mM (in 1mL DMSO) 10mg 50mg 100mg>98.00%Cas No. 1195768-06-9C24H24F3N5O5S3 Dabrafenib (GSK2118436)10mM (in 1mL DMSO) 10mg 50mg 100mg>98.00%Cas No. 1195765-45-7C23H20F3N5O2S2 D-JNKI-1 (AM-111)1mg 5mg 10mg 50mg>98.00%Cas No. 1445179-97-4C164H286N66O40 |
传真号码:021-39596320 021-39921927
QQ: 3004918891 3004905818 3004901493
移动电话:18321818584 15026555973
地址:上海松江新砖公路1155号
产品均为实验试剂,仅供科研实验使用,非药品、非食品、不可用于动物及人体!